Clinical Trials Browser

Phase 2 × trilaciclib × 90 days × Clear all

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06027268 2026-04-22

ToPCourT

Phase 2 Active not recruiting

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06992739 2026-04-14

PROTECT-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05578326 2026-03-30

Study of Trilaciclib and Lurbinectidin

Phase 2 Recruiting

Lung Neoplasms, Neutropenia, Small Cell Lung Carcinoma